Revotar Biopharmaceuticals Ag

Remo Kranich

Ewald Aydt

Anke Busemann

Karin Vollhardt

Gerhard Wolff

Ewald M Aydt

Ewald Mirko Aydt

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning &#x2014;X&#x2014; is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or selectin binding.

Phloroglucinol derivatives having selectin ligand activity

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning &#x2014;X&#x2014; is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Aromatic compounds and their use in medical applications

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols, indices and substituents have the following meaningR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CHR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CH, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl andeither Ror Rmust be HR&#x2550;H, CN, NO, CF, F, Cl, Br, I, CH, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolylthen X is e.g.   or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Non-glycosylated/non-glycosidic/non-peptidic small molecule PSGL-1 mimetics for the treatment of inflammatory disorders

The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-&#x3b1;-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.

Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-&#x3b1;-D-mannopyranosyloxy)-phenyl] hexane

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning&#x2014;X&#x2014; is e.g.  or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning  or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Hydroxylated aromatic compounds

Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning&#x2014;X&#x2014; is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Growing community of inventors

Berlin, Germany

Remo Kranich